PERSPECTIVE THERAPEUTICS INC (CATX) Stock Overview
USA - NYSEARCA:CATX - US46489V3024 - Common Stock
CATX Key Statistics, Chart & Performance
The current stock price of CATX is 2.99 USD. In the past month the price decreased by -12.06%. In the past year, price decreased by -74.07%.
CATX Latest News, Press Relases and Analysis
CATX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About CATX
Company Profile
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company is headquartered in Seattle, Washington and currently employs 138 full-time employees. The company went IPO on 2002-05-31. The firm has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The company is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The firm's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. The company has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Company Info
PERSPECTIVE THERAPEUTICS INC
2401 Elliott Avenue, Suite 320
Seattle WASHINGTON US
Employees: 138
Phone: 12066760900
PERSPECTIVE THERAPEUTICS INC / CATX FAQ
Can you describe the business of PERSPECTIVE THERAPEUTICS INC?
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company is headquartered in Seattle, Washington and currently employs 138 full-time employees. The company went IPO on 2002-05-31. The firm has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The company is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The firm's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. The company has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
What is the current price of CATX stock?
The current stock price of CATX is 2.99 USD. The price increased by 3.82% in the last trading session.
Does PERSPECTIVE THERAPEUTICS INC pay dividends?
CATX does not pay a dividend.
How is the ChartMill rating for PERSPECTIVE THERAPEUTICS INC?
CATX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for PERSPECTIVE THERAPEUTICS INC?
PERSPECTIVE THERAPEUTICS INC (CATX) currently has 138 employees.
What is the market capitalization of CATX stock?
PERSPECTIVE THERAPEUTICS INC (CATX) has a market capitalization of 222.04M USD. This makes CATX a Micro Cap stock.
CATX Technical Analysis
CATX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CATX. While CATX seems to be doing ok healthwise, there are quite some concerns on its profitability.
CATX Financial Highlights
Over the last trailing twelve months CATX reported a non-GAAP Earnings per Share(EPS) of -1. The EPS increased by 39.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.56% | ||
| ROE | -35.74% | ||
| Debt/Equity | 0.01 |
CATX Forecast & Estimates
19 analysts have analysed CATX and the average price target is 13.73 USD. This implies a price increase of 359.22% is expected in the next year compared to the current price of 2.99.
For the next year, analysts expect an EPS growth of -43.54% and a revenue growth -17.6% for CATX